The use of heat to deliver fentanyl via pulmonary drug delivery.
Acute pain
Fentanyl
Inhalation
Journal
International journal of pharmaceutics: X
ISSN: 2590-1567
Titre abrégé: Int J Pharm X
Pays: Netherlands
ID NLM: 101753452
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
received:
22
05
2021
revised:
22
08
2021
accepted:
31
08
2021
entrez:
27
10
2021
pubmed:
28
10
2021
medline:
28
10
2021
Statut:
epublish
Résumé
The golden standard to treat acute pain is by intravenous drug delivery of opioids such as fentanyl or morphine. Intravenous drug delivery requires the placement of an intravenous (IV) port, which can cause infections, dislodgments, and distress to the patients, and therefore a non-invasive method is desirable. Pulmonary drug delivery is a non-invasive method that has been shown to be a good alternative to intravenous administration. New devices have been investigated for treating acute pain by delivering fentanyl by heat. The pure drug, fentanyl, is applied onto a surface which is then heated up to 350 °C and inhaled, resulting in no formation of degradation products. Furthermore, forced degradation of fentanyl has been studied which showed that longer heating time and higher temperatures will result in the formation of degradation products. The evidence indicates that heat can be used to deliver drugs to the lungs where fast onset reaction can be obtained giving fast and non-invasive pain relief.
Identifiants
pubmed: 34704012
doi: 10.1016/j.ijpx.2021.100096
pii: S2590-1567(21)00025-6
pmc: PMC8521112
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
100096Informations de copyright
© 2021 The Author(s).
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Pain Physician. 2011 Jul-Aug;14(4):E343-60
pubmed: 21785485
Anaesthesia. 1991 Nov;46(11):973-6
pubmed: 1750604
Front Pharmacol. 2015 Dec 01;6:286
pubmed: 26648870
Neuropharmacology. 2018 May 15;134(Pt A):121-132
pubmed: 29042317
Int J Nanomedicine. 2016 Sep 06;11:4479-4494
pubmed: 27660441
J Physiol Pharmacol. 2008 Dec;59 Suppl 6:53-79
pubmed: 19218633
Anesth Analg. 2008 Feb;106(2):451-62, table of contents
pubmed: 18227300
Injury. 2008 May;39(5):578-85
pubmed: 17640644
Anesth Analg. 2012 Nov;115(5):1071-7
pubmed: 22984155
J Pharm Biomed Anal. 2010 Nov 2;53(3):325-34
pubmed: 20462721
Pediatr Blood Cancer. 2014 Aug;61(8):1362-8
pubmed: 24610870
Lancet Respir Med. 2014 Jun;2(6):497-506
pubmed: 24899370
J Control Release. 2018 Dec 10;291:116-126
pubmed: 30321577
Drug Metab Dispos. 1996 Sep;24(9):932-9
pubmed: 8886601
Eur Neuropsychopharmacol. 2009 May;19(5):305-8
pubmed: 19269795
Colloids Surf B Biointerfaces. 2017 Mar 1;151:206-214
pubmed: 28013164
J Aerosol Med. 1991 Fall;4(3):151-6
pubmed: 10147676
Anesthesiology. 2000 Sep;93(3):619-28
pubmed: 10969293
Anesthesiology. 1995 Aug;83(2):277-84
pubmed: 7631949
Anticancer Drugs. 2000 Aug;11(7):555-63
pubmed: 11036958
Expert Opin Drug Deliv. 2018 Aug;15(8):821-834
pubmed: 30021074
Nat Rev Drug Discov. 2007 Jan;6(1):67-74
pubmed: 17195033
J Pharm Biomed Anal. 1999 Aug;20(4):705-16
pubmed: 10704140
Br J Anaesth. 1988 Aug;61(2):228-30
pubmed: 3415896
Anaesthesia. 1990 Jun;45(6):449-51
pubmed: 2382801
Int J Pharm. 2011 Jan 17;403(1-2):101-8
pubmed: 20971174
J Infus Nurs. 2015 May-Jun;38(3):189-203
pubmed: 25871866
J Aerosol Med. 1998 Winter;11(4):197-219
pubmed: 10346664
J Pharmacol Exp Ther. 2004 May;309(2):769-75
pubmed: 14752061
Br J Clin Pharmacol. 1998 Jul;46(1):37-43
pubmed: 9690947
Anal Chem. 2015 Nov 3;87(21):10935-41
pubmed: 26434689
J Physiol Pharmacol. 2007 Nov;58 Suppl 5(Pt 2):615-25
pubmed: 18204175
Med Princ Pract. 2016;25 Suppl 2:60-72
pubmed: 26938856
Ann Pharmacother. 2016 Oct;50(10):882-91
pubmed: 27413071
Eur J Pharm Biopharm. 2018 Sep;130:30-38
pubmed: 29890256
Expert Opin Drug Deliv. 2020 Oct;17(10):1459-1472
pubmed: 32684002
Anesth Analg. 1996 Jan;82(1):167-72
pubmed: 8712396
Expert Opin Drug Deliv. 2015 May;12(5):813-25
pubmed: 25496474